Inhalation Sciences strengthens its US IP position with new patent approval

(Stockholm, October 18, 2023) Innovative Swedish MedTech company Inhalation Sciences Sweden AB (ISAB) has strengthened its IP portfolio in the US relating to PreciseInhale® with approval for a new patent.

PreciseInhale®, a unique system with several preclinical exposure modules, has quickly become a natural choice for inhalation scientists worldwide studying how inhaled particles affect the lungs and human health.

PreciseInhale® is already protected by key patent rights, but this so-called divisional application further improves this protection in the strategic and important US market. Through this approval, with patent number US11779944B2, ISAB’s protection in the US is extended until end of 2034.

Precision, user experience, and low cost are some of the features that have positioned PreciseInhale at the forefront of the market globally.

ISAB CEO Manoush Masarrat: “I am pleased that we are creating clearer and stronger exclusivity for our platform technology and one of our most strategic products in the US. As a result, we can confidently continue our efforts to be a leading player in R&D for aerosol and inhalation research. We are in a rapidly growing market, and that includes demands on us and our ability to innovate. We are embracing these demands. Thanks to our strategy, team and expertise I am confident that we have all the prerequisites to meet these demands at speed, further strengthening confidence in our delivery and innovation capabilities”.

For more information about Inhalation Sciences, please contact: Manoush Masarrat, CEO Email: Manoush.Masarrat@inhalation.se Phone: +46 (0)736 289 153